Ensidipine chemotherapy drug or targeted drug?

Ensidipine, also known asEnasidenib, is a targeted therapy for specific cancers that is different from what we typically call chemotherapy. To understand this more clearly, we need to first understand the core differences between targeted drugs and chemotherapy drugs.

The mechanism of action of chemotherapy drugs is mainly to destroy cancer cells by interfering with cell division. But the problem with this method is that it not only affects cancer cells, but also causes damage to other normally dividing cells in the body, such as bone marrow, gastrointestinal tract, and hair follicle cells. Therefore, chemotherapy is often accompanied by a series of serious side effects.

In contrast, targeted drugs are designed to specifically attack specific molecules or signaling pathways in cancer cells, which means they are more selective and less harmful to normal cells. Ensidipine is one such drug that specifically targets the isocitrate dehydrogenase 2 (IDH2) mutation that is frequently seen in acute myeloid leukemia (AML).

IDH2 is an enzyme that plays a key role in cell metabolism. When IDH2 is mutated, it causes abnormalities in cell metabolism, thereby promoting the growth of cancer cells. Ensidipine works by inhibiting this mutated IDH2 enzyme, returning cell metabolism to normal, prompting cancer cells to differentiate and eventually undergo apoptosis, thus preventing the further development of cancer.

Through multiple clinical trials, we have seen significant therapeutic effects from ensidipine. For those AML patients with IDH2 mutations, their disease was significantly relieved and their survival was prolonged after using ensidipine. Of course, like all drugs, ensidipine may cause some side effects, such as nausea, vomiting, diarrhea, etc., but these can be expected and managed.

It is worth mentioning that ensidipine is available in the form of oral tablets and only needs to be taken once a day, which provides patients with great convenience. As a targeted drug, ensidipine is useful for those specific AML patients, especially those with IDH2Patients with mutations are provided with a new, more precise treatment option.

In general, ensidipine, as a targeted drug, has precise treatment methods and relatively few side effects, bringing new treatment opportunities and hope to AML patients. It certainly represents a major advance in cancer treatment compared with chemotherapy drugs.